The heterogeneous landscape of ALK negative ALCL.

TitleThe heterogeneous landscape of ALK negative ALCL.
Publication TypeJournal Article
Year of Publication2017
AuthorsMereu E, Pellegrino E, Scarfò I, Inghirami G, Piva R
JournalOncotarget
Volume8
Issue11
Pagination18525-18536
Date Published2017 Mar 14
ISSN1949-2553
KeywordsAnaplastic Lymphoma Kinase, Humans, Lymphoma, Large-Cell, Anaplastic, Prognosis, Receptor Protein-Tyrosine Kinases
Abstract

Anaplastic Large Cell Lymphoma (ALCL) is a clinical and biological heterogeneous disease including systemic ALK positive and ALK negative entities. Whereas ALK positive ALCLs are molecularly characterized and readily diagnosed, specific immunophenotypic or genetic features to define ALK negative ALCL are missing, and their distinction from other T-cell non-Hodgkin lymphomas (T-NHLs) can be controversial. In recent years, great advances have been made in dissecting the heterogeneity of ALK negative ALCLs and in providing new diagnostic and treatment options for these patients. A new revision of the World Health Organization (WHO) classification promoted ALK negative ALCL to a definite entity that includes cytogenetic subsets with prognostic implications. However, a further understanding of the genetic landscape of ALK negative ALCL is required to dictate more effective therapeutic strategies specifically tailored for each subgroup of patients.

DOI10.18632/oncotarget.14503
Alternate JournalOncotarget
PubMed ID28061468
PubMed Central IDPMC5392347
Related Faculty: 
Giorgio Inghirami, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700